Study of Pembrolizumab Versus Chemotherapy in Mismatch Repair Deficient Advanced or Recurrent Endometrial Carcinoma
The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. The primary study hypotheses are that pembrolizumab is … Continued